Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 rilzabrutinib in adults with moderate-to-severe atopic dermatitis
NL-OMON52158Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rilzabrutinib in atopic dermatitis (AD) (3 arms), sponsored by Sanofi. Primary endpoint: Percent change in Eczema Area and Severity Index score from baseline to week 16. Started Feb 2022; status: active, not recruiting.
02
Drugs
rilzabrutinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON52158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52158.